4-[2-(1H-pyrrol-2-yl)-6-(thiadiazol-4-yl)-3-(1,2-thiazol-3-yl)-5-(2H-triazol-4-yl)-4-pyridinyl]oxadiazole
C18H10N10OS2 — CID 141133670
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4-[2-(1H-pyrrol-2-yl)-6-(thiadiazol-4-yl)-3-(1,2-thiazol-3-yl)-5-(2H-triazol-4-yl)-4-pyridinyl]oxadiazole
4-[2-(1H-pyrrol-2-yl)-6-(thiadiazol-4-yl)-3-(1,2-thiazol-3-yl)-5-(2H-triazol-4-yl)-4-pyridinyl]oxadiazole (PubChem CID 141133670) has the molecular formula C18H10N10OS2 and a molecular weight of 446.48 g/mol. Its IUPAC name is 4-[2-(1H-pyrrol-2-yl)-6-(thiadiazol-4-yl)-3-(1,2-thiazol-3-yl)-5-(2H-triazol-4-yl)-4-pyridinyl]oxadiazole.
Molecular Properties
| Compound Name | 4-[2-(1H-pyrrol-2-yl)-6-(thiadiazol-4-yl)-3-(1,2-thiazol-3-yl)-5-(2H-triazol-4-yl)-4-pyridinyl]oxadiazole |
|---|---|
| PubChem CID | 141133670 |
| Molecular Formula | C18H10N10OS2 |
| Molecular Weight | 446.48 g/mol |
| Exact Mass | 446.05 |
| IUPAC Name | 4-[2-(1H-pyrrol-2-yl)-6-(thiadiazol-4-yl)-3-(1,2-thiazol-3-yl)-5-(2H-triazol-4-yl)-4-pyridinyl]oxadiazole |
| SMILES | c1c[nH]c(-c2nc(-c3csnn3)c(-c3cn[nH]n3)c(-c3conn3)c2-c2ccsn2)c1 |
| InChI | InChI=1S/C18H10N10OS2/c1-2-10(19-4-1)17-15(9-3-5-30-25-9)14(12-7-29-27-23-12)16(11-6-20-26-22-11)18(21-17)13-8-31-28-24-13/h1-8,19H,(H,20,22,26) |
| InChIKey | JYXPBCBWFNIBNZ-UHFFFAOYSA-N |
| XLogP | 3.55 |
| TPSA | 147.84 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 11 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 31 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 446.48 |
| LogP ≤ 5 | 3.55 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 11 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 141133670 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.